vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and P10, Inc. (PX). Click either name above to swap in a different company.
P10, Inc. is the larger business by last-quarter revenue ($81.0M vs $62.1M, roughly 1.3× Cytek Biosciences, Inc.). P10, Inc. runs the higher net margin — 11.7% vs -70.9%, a 82.6% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -4.7%). P10, Inc. produced more free cash flow last quarter ($18.1M vs $-1.8M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 10.7%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
P10, Inc. is a global alternative investment management firm that offers a diversified portfolio of investment solutions spanning private equity, private credit, real assets and venture capital. It primarily caters to institutional clients including pension funds, endowments, foundations, and high-net-worth individuals across North America, Europe, and Asia Pacific.
CTKB vs PX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $81.0M |
| Net Profit | $-44.1M | $9.5M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | 31.9% |
| Net Margin | -70.9% | 11.7% |
| Revenue YoY | 8.1% | -4.7% |
| Net Profit YoY | -557.1% | 79.0% |
| EPS (diluted) | — | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $81.0M | ||
| Q3 25 | $52.3M | $75.9M | ||
| Q2 25 | $45.6M | $72.7M | ||
| Q1 25 | $41.5M | $67.7M | ||
| Q4 24 | $57.5M | $85.0M | ||
| Q3 24 | $51.5M | $74.2M | ||
| Q2 24 | $46.6M | $71.1M | ||
| Q1 24 | $44.9M | $66.1M |
| Q4 25 | $-44.1M | $9.5M | ||
| Q3 25 | $-5.5M | $2.1M | ||
| Q2 25 | $-5.6M | $3.4M | ||
| Q1 25 | $-11.4M | $4.5M | ||
| Q4 24 | $9.6M | $5.3M | ||
| Q3 24 | $941.0K | $1.4M | ||
| Q2 24 | $-10.4M | $7.0M | ||
| Q1 24 | $-6.2M | $5.0M |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | 31.9% | ||
| Q3 25 | -17.6% | 14.1% | ||
| Q2 25 | -23.3% | 24.4% | ||
| Q1 25 | -36.1% | 16.6% | ||
| Q4 24 | 5.2% | 26.9% | ||
| Q3 24 | -8.2% | 11.9% | ||
| Q2 24 | -18.3% | 23.7% | ||
| Q1 24 | -23.9% | 18.3% |
| Q4 25 | -70.9% | 11.7% | ||
| Q3 25 | -10.5% | 2.8% | ||
| Q2 25 | -12.2% | 4.7% | ||
| Q1 25 | -27.5% | 6.7% | ||
| Q4 24 | 16.8% | 6.2% | ||
| Q3 24 | 1.8% | 1.9% | ||
| Q2 24 | -22.4% | 9.8% | ||
| Q1 24 | -13.8% | 7.6% |
| Q4 25 | — | $0.08 | ||
| Q3 25 | — | $0.02 | ||
| Q2 25 | — | $0.03 | ||
| Q1 25 | — | $0.04 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $0.01 | ||
| Q2 24 | — | $0.06 | ||
| Q1 24 | — | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $28.2M |
| Total DebtLower is stronger | — | $373.2M |
| Stockholders' EquityBook value | $341.7M | $403.5M |
| Total Assets | $461.5M | $928.3M |
| Debt / EquityLower = less leverage | — | 0.93× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $28.2M | ||
| Q3 25 | $93.3M | $40.0M | ||
| Q2 25 | $75.5M | $33.4M | ||
| Q1 25 | $95.3M | $74.4M | ||
| Q4 24 | $98.7M | $67.5M | ||
| Q3 24 | $162.3M | $61.5M | ||
| Q2 24 | $177.9M | $31.2M | ||
| Q1 24 | $168.8M | $29.0M |
| Q4 25 | — | $373.2M | ||
| Q3 25 | — | $393.4M | ||
| Q2 25 | — | $373.0M | ||
| Q1 25 | — | $357.2M | ||
| Q4 24 | — | $319.8M | ||
| Q3 24 | — | $319.4M | ||
| Q2 24 | — | $300.6M | ||
| Q1 24 | — | $314.0M |
| Q4 25 | $341.7M | $403.5M | ||
| Q3 25 | $378.6M | $396.8M | ||
| Q2 25 | $377.6M | $388.9M | ||
| Q1 25 | $379.6M | $374.3M | ||
| Q4 24 | $395.7M | $386.9M | ||
| Q3 24 | $385.5M | $394.1M | ||
| Q2 24 | $389.1M | $396.9M | ||
| Q1 24 | $392.6M | $400.1M |
| Q4 25 | $461.5M | $928.3M | ||
| Q3 25 | $494.9M | $936.0M | ||
| Q2 25 | $493.3M | $932.2M | ||
| Q1 25 | $482.6M | $877.4M | ||
| Q4 24 | $499.5M | $869.3M | ||
| Q3 24 | $491.2M | $857.0M | ||
| Q2 24 | $483.7M | $823.2M | ||
| Q1 24 | $492.1M | $832.8M |
| Q4 25 | — | 0.93× | ||
| Q3 25 | — | 0.99× | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | 0.95× | ||
| Q4 24 | — | 0.83× | ||
| Q3 24 | — | 0.81× | ||
| Q2 24 | — | 0.76× | ||
| Q1 24 | — | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $23.0M |
| Free Cash FlowOCF − Capex | $-1.8M | $18.1M |
| FCF MarginFCF / Revenue | -2.9% | 22.3% |
| Capex IntensityCapex / Revenue | 1.6% | 6.0% |
| Cash ConversionOCF / Net Profit | — | 2.43× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $14.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $23.0M | ||
| Q3 25 | $-3.9M | $-8.6M | ||
| Q2 25 | $108.0K | $13.4M | ||
| Q1 25 | $-125.0K | $-4.7M | ||
| Q4 24 | $2.0M | $101.0M | ||
| Q3 24 | $13.2M | $27.5M | ||
| Q2 24 | $6.2M | $34.8M | ||
| Q1 24 | $4.0M | $11.0M |
| Q4 25 | $-1.8M | $18.1M | ||
| Q3 25 | $-4.6M | $-9.5M | ||
| Q2 25 | $-1.5M | $11.6M | ||
| Q1 25 | $-974.0K | $-6.0M | ||
| Q4 24 | $1.1M | $96.6M | ||
| Q3 24 | $12.2M | $25.2M | ||
| Q2 24 | $5.2M | $33.9M | ||
| Q1 24 | $3.4M | $10.7M |
| Q4 25 | -2.9% | 22.3% | ||
| Q3 25 | -8.7% | -12.6% | ||
| Q2 25 | -3.2% | 15.9% | ||
| Q1 25 | -2.3% | -8.9% | ||
| Q4 24 | 1.9% | 113.6% | ||
| Q3 24 | 23.7% | 34.0% | ||
| Q2 24 | 11.0% | 47.7% | ||
| Q1 24 | 7.6% | 16.2% |
| Q4 25 | 1.6% | 6.0% | ||
| Q3 25 | 1.3% | 1.2% | ||
| Q2 25 | 3.5% | 2.5% | ||
| Q1 25 | 2.0% | 1.9% | ||
| Q4 24 | 1.6% | 5.2% | ||
| Q3 24 | 2.0% | 3.0% | ||
| Q2 24 | 2.3% | 1.3% | ||
| Q1 24 | 1.3% | 0.4% |
| Q4 25 | — | 2.43× | ||
| Q3 25 | — | -4.01× | ||
| Q2 25 | — | 3.96× | ||
| Q1 25 | — | -1.05× | ||
| Q4 24 | 0.21× | 19.12× | ||
| Q3 24 | 14.05× | 19.54× | ||
| Q2 24 | — | 4.98× | ||
| Q1 24 | — | 2.18× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
PX
| Management Fees | $78.1M | 96% |
| Advisory Fees | $1.8M | 2% |
